European equity investors in 2026 have more screener options than at any point in the past — but the tools vary enormously in European coverage quality, pricing, and what workflows they actually support. This comparison covers every major screener with meaningful European relevance, scored on the criteria that matter most for European fundamental investing.
Last updated: May 2026.
Evaluation criteria
For this comparison, each screener is evaluated on six criteria:
- European exchange coverage — which exchanges are included, and how complete is fundamental data for each
- Microcap coverage — data quality for companies below €500M, especially on alternative markets (Euronext Growth, First North, EGM)
- Fundamental filter quality — P/E, P/B, ROE, EV/EBITDA, margins — reliable for European names, not just US ones
- Interface speed — how fast filter results update; slow screeners kill the workflow
- Price — monthly cost for the tier that unlocks the useful features
- Free access — whether meaningful screening is possible without paying
The screeners
ScreenerHero
What it is: A stock screener built specifically for multi-geography fundamental screening — US, Canada, and all European exchanges in a single tool.
European coverage: All major European exchanges (XETRA, Euronext Paris, Euronext Amsterdam, BME, Borsa Italiana, Euronext Brussels, Euronext Lisbon, Nasdaq Stockholm, Oslo Bors) plus alternative markets: Euronext Growth Paris, Nasdaq First North (Stockholm, Copenhagen, Helsinki), EGM Milan, and GPW NewConnect. Fundamental data — P/E, ROE, EV/EBITDA, margins — is reliable down to microcap level including alternative market listings.
Microcap coverage: Strong. Alternative market listings — where most European microcaps trade — are a core product priority, not an afterthought.
Interface: Desktop-first, data-dense. Filter results update sub-second. Same design philosophy as Finviz — dense tables, decision-oriented, minimal friction.
Price: Free (full screener, no account) · €29/month Pro (saved screens, alerts, unlimited results)
Best for: Investors who screen European stocks by fundamental criteria. Particularly strong for European microcap coverage that most other tools miss.
Honest weakness: No options data, no earnings transcripts, basic charts. Not a research terminal — a screener.
TradingView
What it is: The world's leading charting platform, with a screener as a secondary feature.
European coverage: All major European exchanges at the price data level. Fundamental data quality for European small caps — particularly on alternative markets — is inconsistent. Companies below €300M on Euronext Growth or First North often lack usable P/E or EV/EBITDA data.
Microcap coverage: Weak. Alternative market fundamental data is sparse and often stale.
Interface: Chart-first. The screener is nested within a charting workflow. Sub-second filter updates on premium plans.
Price: Free (account required, filters restricted) · $15–60/month
Best for: Chart-driven investors. TradingView's charting quality has no peer — nothing comes close for technical analysis. European fundamental screening below large cap is not its strength.
Honest weakness: Screener is secondary to charting. European small cap fundamental data quality is a known limitation, particularly for alternative markets.
Stockopedia
What it is: A score-driven research platform built around StockRanks — a composite of quality, value, and momentum scores.
European coverage: UK-primary, with continental European coverage. The US is only available on the more expensive €80/month plan. No Canadian coverage. European microcap coverage has gaps, especially outside the UK.
Microcap coverage: Partial. UK small cap coverage is strong. Continental European microcap data is inconsistent, particularly for alternative markets.
Interface: Card-based and editorial-first. StockRanks scores are displayed prominently. Not a raw-filter screener — it is built for investors who prefer pre-computed composite signals.
Price: €60/month (Europe only) · €80/month (Europe + US)
Best for: UK and European investors who want a thoughtful composite scoring system rather than raw filters. StockRanks (Quality × Value × Momentum) is genuinely well-designed. The editorial content and community are above average.
Honest weakness: €80/month is 2.7× ScreenerHero for less geographic coverage. UX is dated by 2026 standards. Raw-filter screeners are hidden behind the StockRanks interface.
MarketScreener
What it is: A European market intelligence platform with analyst estimates, news, and a screener built on top of a broad fundamental database.
European coverage: One of the broadest European fundamental databases available — 300–600 filters across major and minor European exchanges. Strong on analyst consensus estimates and earnings forecasts, which most screeners lack.
Microcap coverage: Good coverage breadth. Data quality for very small companies is variable, but MarketScreener's European coverage is more thorough than most non-specialist tools.
Interface: Table-based but slow — filter changes require page reloads in many cases. Built around an editorial content model rather than rapid iteration.
Price: Free (limited) · ~€30–34/month
Best for: Investors who want analyst consensus alongside screening. The broadest European fundamental database for retail investors. Useful as a complement to faster screeners for cross-referencing data.
Honest weakness: The screener UX is slow compared to ScreenerHero or Finviz. The platform is built around news and editorial content — the screener is a feature, not the product.
TIKR
What it is: A platform that makes institutional-quality financial data — 20-year historical financials, earnings transcripts, segment data — accessible at consumer prices.
European coverage: 100,000+ stocks listed globally including Europe. For European companies above €1B market cap, data is generally good. Below €500M — especially on alternative markets — fundamental data coverage is thin. The companies are listed, but P/E and EV/EBITDA filters often return no data.
Microcap coverage: Weak in practice for European names. Global breadth ≠ European microcap depth.
Interface: Clean and functional. Less dense than ScreenerHero or Finviz. Better suited for deep-dive individual company research than rapid bulk screening.
Price: Free (friction-heavy) · $10–15/month Plus · $40–55/month Pro
Best for: Investors who need 20-year historical financial data and earnings call transcripts. TIKR Pro is a genuinely good product for long-term investors who research individual companies in depth. The screening capability is weaker than the research capability.
Honest weakness: European microcap fundamental data has significant gaps. The entry price (TIKR Plus at $10–15/month) comes with meaningful feature restrictions.
Finviz
What it is: The industry-standard US stock screener. The reference point for dense, fast screening.
European coverage: None. Finviz covers US equities (NYSE, NASDAQ, OTC) and a small number of European ADRs listed in the US. No European exchange coverage.
Microcap coverage: N/A for Europe. Covers US micro and small caps well.
Interface: The benchmark. Sub-second filter updates, densest table layout in the category, excellent heatmap. Finviz Elite at $39.50/month is worth it for US-focused investors.
Price: Free (ads, delayed) · $39.50/month Elite · $299.50/year
Best for: US equity investors. Finviz is the best US screener available. It has no relevance for European equity screening.
Honest weakness: No European coverage whatsoever. US-only.
Koyfin
What it is: A professional research terminal — dashboards, charting, macro data, and portfolio tracking — with a screener attached.
European coverage: Global, including European large and mid caps. Microcap coverage below €300M has gaps, particularly for alternative markets.
Microcap coverage: Partial. Larger European names are well-covered; alternative market listings are inconsistent.
Interface: Dashboard-first. Professional charting, custom widgets, macro overlays. The screener is one feature among many — not the primary workflow.
Price: $39/month Plus · $79/month Pro
Best for: Investors who want a Bloomberg-lite experience — dashboards, macro overlays, multi-asset charting. If screening is 20% of your workflow and research/charting is 80%, Koyfin makes sense. If screening is your primary activity, you are paying for features you are not using.
Honest weakness: $39–79/month is expensive if screening is your primary use case. European microcap coverage has gaps.
Stock Rover
What it is: A deep fundamental screener for US and Canadian equities with 700+ metrics.
European coverage: None. Stock Rover covers US stocks and TSX (Canada) only. No European exchange coverage.
Microcap coverage: N/A for Europe. Strong for North American small caps.
Interface: Feature-rich but complex. 700+ metrics is impressive — the UX reflects it. Better for power users who need every variation of a fundamental ratio than for fast screening.
Price: Free (limited) · $7.99/month Basic · $27.99/month Premium Plus
Best for: US and Canadian equity investors with complex screening requirements or heavy dividend analytics needs. Best dividend research suite in the category.
Honest weakness: No European coverage. Steep learning curve.
Summary comparison table
| Screener | EU Large Cap | EU Microcap | Alt Markets | US | Canada | Price/mo |
|---|---|---|---|---|---|---|
| ScreenerHero | ✓ | ✓ | ✓ | ✓ | ✓ | €29 |
| TradingView | ✓ | − | − | ✓ | ✓ | $15–60 |
| Stockopedia | ✓ | − | − | € plan | ✗ | €60–80 |
| MarketScreener | ✓ | ✓ | − | − | ✗ | ~€30 |
| TIKR | ✓ | − | − | ✓ | − | $15–55 |
| Finviz | ✗ | ✗ | ✗ | ✓ | ✗ | $39.50 |
| Koyfin | ✓ | − | − | ✓ | − | $39–79 |
| Stock Rover | ✗ | ✗ | ✗ | ✓ | ✓ | $27.99 |
✓ = strong · − = partial or inconsistent · ✗ = not covered
Prices as of May 2026. "Alt markets" = Euronext Growth, Nasdaq First North, EGM Milan, GPW NewConnect.
Recommendations by use case
You screen European stocks by P/E, ROE, EV/EBITDA as your main workflow: → ScreenerHero. Free, fast, full European coverage including microcaps on alternative markets.
You want charts alongside European equity data: → TradingView for large caps. ScreenerHero if microcap fundamental screening matters.
You want composite scores (Quality × Value × Momentum) rather than raw filters: → Stockopedia. Well-designed system — expensive but coherent.
You need analyst consensus estimates and earnings forecasts for European stocks: → MarketScreener. The broadest EU fundamental database, accepts slow UX.
You need 20-year financial history and earnings transcripts: → TIKR Pro. Historical depth is a genuine advantage. Accept the EU microcap gaps.
You screen US stocks exclusively: → Finviz Elite. Best-in-class for US equities.
You want a professional research terminal (dashboards, macro, charting) with screening: → Koyfin Plus. Accepts $39/month for a broader tool.
You screen US and Canadian stocks with deep metric needs: → Stock Rover Premium Plus. 700+ metrics — accept no EU coverage.
The European microcap gap — why it matters
The most significant differentiation in this comparison is coverage of European alternative markets — Euronext Growth Paris, Nasdaq First North (Stockholm, Copenhagen, Helsinki), EGM Milan, and GPW NewConnect (Warsaw).
These markets collectively list over 800 companies with market caps between €10M and €300M. Many are profitable, growing, and structurally under-owned because they fall below the minimum position size of institutional investors and below the European coverage threshold of most global screeners.
The tools that cover these markets with reliable fundamental data — where you can actually filter by P/E < 15 and EV/EBITDA < 10 and get meaningful results — are ScreenerHero and, to a lesser extent, MarketScreener. TradingView, TIKR, Koyfin, Stockopedia, Finviz, and Stock Rover list many of these companies but return incomplete or absent fundamental data for a large proportion of them.
For investors whose strategy includes European microcaps, this gap is not a minor inconvenience — it is the difference between having a usable tool and not having one.
Open ScreenerHero free → — no account required. European stocks from XETRA, Euronext, BME, Borsa Italiana, First North, Euronext Growth, EGM, and NewConnect, filtered by the fundamentals that matter. Pro at €29/month.